Skip to content

Vaginal Flora for Treatment of Bacterial Vaginosis

Vaginal Flora Transplantation for Recurrent Bacterial Vaginosis

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02236429
Acronym
VFT
Enrollment
10
Registered
2014-09-10
Start date
2015-06-30
Completion date
2026-03-31
Last updated
2025-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Bacterial Vaginitis

Keywords

bacterial vaginitis, vaginal flora, microbiome

Brief summary

Bacterial vaginosis (BV) is the most common vaginal infection in women. It is caused by a vaginal bacterial imbalance. Treatment with antibiotics is the standard of care but there is a high rate of recurrence. Almost half of women successfully treated suffer a recurrence within three months. Complications include risk factors for premature birth, increased transmission of sexually transmitted diseases and higher risk for carcinoma of cervix. The investigators proposed study is a cost effective treatment based on returning the normal microbial balance to the vagina. The investigators propose to transfer normal vaginal flora from healthy individuals to women with BV and thus restore normal vaginal flora and cure this disorder.

Interventions

BIOLOGICALvaginal flora transplant

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* recurrent BV (4 or more incidences in the past year) * recurrence of BV in less than 2 months of antibiotic treatment or need for prophylactic antibiotic * 3/4 Amsel criteria and Nugent criteria greater or equal to 7

Exclusion criteria

* pregnancy or planned pregnancy during the study period * other known diseases * carriers of Hep B and C * HIV or syphilis positive

Design outcomes

Primary

MeasureTime frameDescription
relief of bacterial vaginosis12 monthClinical cure, i.e., absence of vaginal discharge and malodor

Secondary

MeasureTime frameDescription
Laboratory parameters12 monthsabsence of all Amsel criteria and Nugent score\<3.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026